A topical gel made from a class of common blood pressure medications has been found to accelerate the healing process of chronic skin wounds...
List view / Grid view
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
4 May 2016 | By Victoria White, Digital Content Producer
The heart failure treatment market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, according to research and consulting firm GlobalData.
21 March 2016 | By Victoria White
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ heart failure drug, Entresto (sacubitrial/valsartan).
7 March 2016 | By Victoria White
The Scottish Medicines Consortium (SMC) has accepted three new medicines for routine use in NHS Scotland.
25 November 2015 | By Victoria White
The European Commission has granted marketing authorisation to Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).